Listen to Gynecologic Oncology

Editor's Choice:  Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleeding

Editorial: Tampon-based methylated DNA testing for endometrial cancer: Promising innovation, but prudence before practice
Hosted by: 
Charles N. Landen Jr., MD; University of Virginia Charlottesville, VA, USA
Featuring: 
Jamie N. Bakkum-Gamez, MD; Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA
John B. Kisiel, MD; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
Joy M. Davis MD; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review

Moderator:
Ursula A. Matulonis, MD; Dana-Farber Cancer Institute
Speakers:
Bhavana Pothuri, MD; Perlmutter Cancer Center, NYU Langone Health
Róisín E. O’Cearbhaill, MD; Gynecologic Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center; Department of Medicine, Weill Cornell Medical College
Yvette Drew, MBBS, PhD; BC Cancer Centre Vancouver and University of British Columbia
Christina Washington, MD; Stephenson Cancer Center, University of Oklahoma

Ursula A. Matulonis, MD, is joined by Bhavana Pothuri, MD, Róisín O’Cearbhaill, MD, Yvette Drew, MBBS, PhD, and Christina Washington, MD, to discuss recent updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors (PARPi) in ovarian cancer. Based on the recent Society of Gynecologic Oncology clinical practice review published in Gynecologic Oncology, the speakers review the evolving role of PARP inhibitors and the clinical implications of updated regulatory approvals.
The panel explores current evidence supporting PARP inhibitor use in ovarian cancer, including considerations for patient selection, biomarker testing, maintenance therapy, and safety considerations. The speakers also discuss how recent changes in FDA indications may affect clinical decision-making and treatment sequencing in practice.
This podcast highlights practical clinical pearls to help guide practitioners in the appropriate integration of PARP inhibitors into the management of ovarian cancer patients.

This podcast was developed by the Society of Gynecologic Oncology for Gynecologic Oncology.
Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  Same day discharge after minimally invasive interval debulking surgery in advanced stage ovarian cancer
Editorial: Same-day discharge in advanced ovarian cancer as a milestone of surgical evolution and patient selection
Hosted by: 
Gregg Nelson, MD, PhD, FRCSC University of Calgary, Calgary, Alberta Canada
Featuring: 
Surabhi Tewari, MD, Department of Obstetrics and Gynecology, Mass General Brigham, Harvard Medical School, Boston, MA, USA
Alexander Melamed, MD MPH, Department of Obstetrics and Gynecology, Mass General Brigham, Harvard Medical School, Boston, MA, USA
Jose Alejandro Rauh-Hain, MD MPH, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statement

Hosted by:
Jose Alejandro Rauh-Hain, MD MPH
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Featuring:
Charles A. Powell, MD, MBA
Division of Pulmonary, Critical Care and Sleep Medicine, Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial
Editorial: Commentary on: Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup Canadian Cancer Trials Group Cx.5/SHAPE trial
Hosted by: Gregg Nelson, MD, PhD, FRCSC University of Calgary, Calgary, Alberta Canada

Featuring: Janice S. Kwon  MD, MPH, FRCSC, University of British Columbia, Vancouver, Canada and  R. Wendel Naumann, MD Atrium Health, Wake Forest University School of Medicine, Charlotte, NC 28203, USA

Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net